T-Cell Lymphoma in a Patient with Neurofibromatosis Type 1 and AIDS

Izana Junqueira de Castro a, Esther Botelho Soares da Silva a, Talita Rezende dos Santos a, Amanda Barroso de Freitas a, Inara Junqueira de Castro b, Alessandra Santos Portela a, Marilza Campos de Magalhães a, Karina Lebeis Pires a, Guilherme Almeida Rosa da Silva a, Marcelo Costa Velho Mendes de Azevedo a

a Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil; b União das Faculdades dos Grandes Lagos (UNILAGO), São José do Rio Preto, Brazil

Keywords
HIV · AIDS · Neurofibromatosis type 1 · T-cell lymphoma

Abstract
Neurofibromatosis type 1 (NF1) and AIDS are risk factors for the development of malignant neoplasms, including hematological malignancies, such as non-Hodgkin lymphoma. NF1 is an autosomal dominant disease that primarily manifests as café-au-lait spots, dermal neurofibromas, axillary and/or inguinal ephelides or freckles, plexiform neurofibromas, Lisch nodules, and bone deformities. In this report, we present a 38-year-old female patient with NF1 from childhood and AIDS who developed peripheral T-cell lymphoma with good response to chemotherapeutic treatment.
Introduction

Neurofibromatosis (NF) is a denomination comprising 3 diseases, NF type 1 (NF1), NF type 2, and schwannomatosis, all of which are diseases of autosomal dominant genetic origins. NF1 is the most common disease, with an incidence of 1/3,000 live births [1], and it has also been referred to as peripheral or classical NF [2], while NF2 and schwannomatosis affect approximately 1/25,000 live births [3]. NF is the most common phakomatosis, which includes congenital developmental malformations that simultaneously affect the skin, retina, and nervous system, such as Sturge-Weber syndrome, tuberous sclerosis, and Von Hippel-Lindau syndrome. NF1 accounts for 90% of all cases and is one of the most common autosomal dominant diseases in humans [4]. One of the main characteristics of this disease is its systemic and progressive involvement, which presents impairment of neurological functions and physical deformities. NF1 primarily manifests as café-au-lait spots, dermal neurofibromas, axillary and/or inguinal ephelides or freckles, plexiform neurofibromas, Lisch nodules, and bone deformities [2].

NF1 commonly occurs in 1 or 2 generations, but in some families it can occur in 4–6 generations. The term "expressiveness" refers to the variability of physical or clinical signs associated with a given gene. NF1 is one of the genetic diseases that best exemplifies this phenomenon, as there is ample clinical variability, even intrafamilial variability. In addition, a severely affected patient may produce offspring with a milder clinical picture and vice versa [5].

Currently, the National Institutes of Health (NIH) criteria for the diagnosis of NF1 include 2 or more of the following criteria: 6 or more café-au-lait spots >5 mm in diameter in prepubertal patients or >15 mm in diameter in postpubertal patients; 2 or more neurofibromas of any type or a plexiform neurofibroma; freckles in an axillary or inguinal area; glioma of the optic nerve; 2 or more Lisch nodules; a distinctive bone lesion, such as sphenoid wing dysplasia or thinning of the bone cortex with or without pseudoarthrosis; and a first-degree relative (parents, siblings, or children) with NF1 based on the above criteria [6].

The 5 subtypes of neurofibromas are cutaneous, subcutaneous, nodular, plexiform, and diffuse [7]. Other associated findings include visual disturbances, cognitive disorders, growth problems, and musculoskeletal disorders [7]. The diagnosis is primarily made through clinical criteria and the observation of changes on a chest X-ray [2, 8].

Mutation of the gene encoding neurofibromin is the main factor contributing to the development of NF1. The NF1 gene was cloned and mapped to human chromosome 17q11.2 [9, 10]. The functions of neurofibromin are not fully understood, and this protein can act as a tumor suppressor [11].

Patients with NF1 have an increased risk of malignancies estimated to be at 5–15% [12]. Thus, only a small number of malignant tumors, which typically appear before 38 years of age from an old neurofibroma, have been reported as complications of this disease [11, 12]. These malignancies are an important cause of morbidity and mortality in NF1 [6].

NF1 is associated with the development of malignancies, including those of neural crest origin, such as pheochromocytoma, neuroblastoma, and melanoma. Among the tumors that do not originate in the neural crest are Wilms tumor, rhabdomyosarcoma, malignant nodular hidradenoma, and leukemia. Malignant peripheral nerve sheath tumors are associated with NF1 and are a potential cause of mortality in adult patients with NF1 [6]. Few reports
concern the development of malignant lymphomas in patients with NF1 [13], and the mechanism of the association between neurofibromatosis and malignant lymphomas has not yet been elucidated [14]. Malignant lymphoma is defined as a solid tumor of the immune system, and there are 2 types of lymphomas: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) [14].

NHLs are a heterogeneous group of lymphoproliferative diseases typically affecting nodal and extranodal sites and producing a plethora of nonspecific clinical features [4]. There are several classifications of NHL. To identify the type of NHL, it is necessary to collect a sample of tissue for later laboratory and microscopic analyses. Most cases of NHL affect B lymphocytes [4].

AIDS-related NHL is typically a late event in the course of HIV infection and is associated with a low CD4+ T-cell count and a high viral load. The most common AIDS-related NHLs are B-cell lymphomas, aggressive and generally high-degree malignancies, such as large cell and Burkitt lymphomas [4].

The objective of the present study is to report a case of the association of NF1 and AIDS in a female patient who developed a T-cell NHL as well as to discuss the literature concerning this association.

Case Report

The patient was a 38-year-old, black, single female from the state of Rio de Janeiro, who was HIV positive (diagnosed in August 2014, presenting with pneumonia and herpes zoster), with irregular use of antiretroviral therapy – tenofovir 300 mg + lamivudine 300 mg + efavirenz 600 mg. At the time of admission, the HIV viral load was recorded at 2,558 copies per mL, with TCD4+ lymphocyte counts at 170 cells/mm³ and TCD8+ lymphocytes at 1,478 cells/mm³. The patient had been diagnosed as a carrier of NF1 during childhood. At the time of hospitalization, the patient had axillary ephelides (Fig. 1), café-au-lait spots, and neurofibromas in the frontal trunk (Fig. 2), upper limbs, and lower limbs. Her family members (mother and sister) also presented with neurofibromas.

In June 2014, she noticed a mobile, fibroelastic mass of approximately 1 cm in the right inguinal region accompanied by hyperemia, flushing, edema, and local pain of high intensity, pulsatile, without mitigating or aggravating factors. She also had nocturnal sweating, dry cough, and unmeasured and unmedicated fever. The symptoms evolved, with worsening of the pain and a progressive increase of the mass, with fistulization of liquid and whitish secretion with traces of blood. She also reported a weight loss of 13 kg in 5 months. The patient denied dyspnea, gastrointestinal tract abnormalities, inappetence, and insomnia.

At the time of admission, there were palpable posterior cervical lymph nodes, palpable left popliteal lymph nodes without phlogistic signs, and palpable liver with 20 cm hepatomegaly. The hemogram showed pancytopenia, and the patient underwent a platelet transfusion. Computed tomography of the chest revealed bronchiectasis and the absence of a mediastinal mass. A biopsy of the inguinal mass was performed, and the histopathological examination revealed a peripheral CD8+ T-cell lymphoma (Fig. 3) and HTLV-1 serology, with a nonreactive result.
After diagnosis, the patient was staged as stage III according to Ann Arbor Staging. She received treatment with a CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone) chemotherapy cycle during hospitalization, presenting a satisfactory evolution with a reduction of lymph node size in the posterior cervical, left popliteal, and right inguinal regions. Outpatient follow-up was conducted at the Immunology and Hematology Department to complete 5 more CHOEP cycles, clinical evaluation, and antiretroviral treatment follow-up.

In 2 years, there was no recurrence of lymphoma. We also observed a weight gain of 21 kg, undetected viral load and the CD4+ T-lymphocyte count increased to 231 copies/mm³.

Discussion

Lymphomas in patients with NF1 have rarely been reported, although a population-based study in the UK concludes that these patients are 3.3 times more likely to present diffuse NHL than patients without NF1 [15]. A PubMed search was performed with the keywords "neurofibromatosis type 1" and "lymphoma," and T-cell lymphoma was the immunophenotype most frequently reported in patients with NF1 (Table 1).

The peripheral T-cell lymphoma presented in this study presents a heterogeneous morphological group of aggressive neoplasias that share a mature T-cell immunophenotype associated with a bleak prognosis and low response to CHOP chemotherapy treatment [4]. However, in this case, the patient’s response to the scheme was satisfactory.

Subsequently, the keywords "neurofibromatosis type 1," "lymphoma," and "AIDS" were inserted, and this case was the first describing T-cell lymphoma in a patient with NF1 and AIDS.

AIDS is characterized by severe immunosuppression, leading to the occurrence of cachexia, opportunistic infections, and neoplasias. AIDS-defining neoplastic diseases include Kaposi sarcoma, NHL, and invasive carcinoma of the cervix [4].

The B-cell phenotype is the most common lymphoma in AIDS, and grade III or IV immunoblastic lymphoma, Burkitt lymphoma, and primary central nervous system lymphoma are the 3 major types of lymphoma associated with AIDS. Lymphomas are a late manifestation of HIV infection that typically occur in patients with few CD4+ T cells (<200 cells/mm³) [4]. As the disease progresses, the risk of developing lymphomas increases [4]. In this case, the patient’s TCD4+ cell count of 170 cells/mm³ was expected for the manifestation of lymphoma in the course of AIDS.

The clinical picture of NHL is primarily characterized by lymph node enlargement, nocturnal sweating, fever, and weight loss, of which the latter 3 characteristics are known as B symptoms [4]. The patient in this case had a clinical presentation compatible with the description in the literature, and lymph node tuberculosis, cat scratch disease, deep mycoses, and suppurative lymphadenitis were differential diagnoses.

Thus, we conclude that the clinical course of this case is remarkable in 2 important aspects: (1) the peripheral T-cell NHL phenotype, which is of rare prevalence in patients with AIDS; and (2) the fact that the patient presented 2 risk factors for the manifestation of malignancies and the questioning of which of these conditions contributed most to this manifestation or whether the risk factors contributed equally to the appearance of NHL.
In addition, the variety of malignant tumors, including lymphomas, should be considered in patients with NF1, as T-cell lymphoma may not be a rare complication in such patients, and NF1 may be a risk for the development of this type of malignancy.

Statement of Ethics

The patient in this study gave informed consent and the study protocol was approved by the Ethics Committee of the Hospital Universitário Gaffrée e Guinle.

Disclosure Statement

The authors have no conflicts of interest to disclose with any of the material presented within the manuscript.

References

1. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1–6.
2. Muniz MP, Ferraz Filho JR, Souza AS, Zanussi SH, Pavarino-Bertelli EC, Golani-Bertollo EM: Neurofibromatose tipo 1: aspectos clínicos e radiológicos. Rev Imagem 2006;28:87–96.
3. Ferner RE, Huson SN, Thomas N, Moss C, Willshaw H, Evans DG, et al: Guideline for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81–88.
4. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J: Harrison. Princípios de Medicina Interna, ed 18. McGraw-Hill-Artmed.
5. Darrigo Jr LG, Bonalumi Filho A, D’Alessandro DSM, Geller M: Neurofibromatose tipo 1 em crianças: aspectos clínicos e radiológicos. Rev Paul Pediatr 2008;26:176–182.
6. Courtney RH, McBurney EI: Cutaneous T-cell lymphoma in a patient with neurofibromatosis type 1. Cutis 2003;72:27–30.
7. Eichenfield LF, Levy ML, Paller AS, et al: Guidelines of care for neurofibromatosis type 1. J Am Acad Dermatol 1997;37:625–630.
8. Beiro AC, Dantas JFC, Conte Neto N, Nasciben MB, Scarso Filho J: Neurofibromatose: uma desordem hereditária a relato de caso de ocorrência em mãe e filha. R Ci Med Biol 2008;7:193–197.
9. Cawthon RM, Weiss R, Xu G, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O’Connell P, White R: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193–201.
10. Li Y, O’Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D: Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995;25:9–18.
11. Kim SJ, Seo JH, Lee SW, Han E, Lee ES, Cha SH, Seo BK: A case of non-Hodgkin’s lymphoma in a patient with neurofibromatosis type 1. Korean J Intern Med 2003;18:202–205.
12. Luwungaran S, Aewwarakul CU: Diffuse large B cell lymphoma presenting as Horner’s syndrome in a patient diagnosed with neurofibromatosis type 1: a case report and review of the literature. J Med Case Rep 2012;6:8.
13. Uyttebroeck A, Legius E, Brock P, Van de Cassee W, Casaer P, Casteels-Van Daele M: Consecutive glioblastoma and B cell non-Hodgkin’s lymphoma in a young child with von Recklinghausen’s neurofibromatosis. Med Pediatr Oncol 1995;24:46–49.
14. Dohi O, Hatori M, Ichinokasama R, Hosaka M, Hashimoto S, Kokubun S: Diffuse large B-cell lymphoma arising in a patient with neurofibromatosis type I and in a patient with neurofibromatosis type II. Tohoku J Exp Med 2006;208:169–176.
Fig. 1. Ephelides and café-au-lait spots in the axillary region.

Oki M, Nanao T, Shinoda T, Tsuda A, Yasuda A, Seki T, Ozawa H, Nakamura N, Takagi A: Primary effusion lymphoma-like lymphoma in a patient with neurofibromatosis type 1. Tokai J Exp Clin Med 2016;41:123–129.
Fig. 2. Café-au-lait spots and neurofibromas in the umbilical region.

Fig. 3. Histopathological evidence of peripheral CD8+ T-cell lymphoma.
Table 1. Lymphoma case reports in patients with NF1

| Authors             | Cases, n | Age, years | Gender | Lymphoma                                | Outcome          |
|---------------------|----------|------------|--------|-----------------------------------------|------------------|
| Oki et al.          | 1        | 73         | F      | PEL like                                | Cure             |
| Varan et al.        | 1        | 4          | M      | Lymphoblastic T cells                   | Death            |
| Reich et al.        | 1        | 28         | F      | T cells                                 | Cure             |
| Claudy-Omwugaje et al.| 1       | 59         | M      | Large B cells                           | Cure             |
| de Blank et al.     | 1        | 6          | M      | HL with nodular lymphocytic predominance| Cure             |
| Inceoik et al.      | 2        | 8/7        | M/F    | HL/NHL T cells                          | 2 cures          |
| Soda et al.         | 1        | 70         | M      | Large B cells                           | Cure             |
| Cheuk et al.        | 1        | 21         | M      | Anaplastic large cells                  | Death            |
| Eoli et al.         | 1        | 60         | F      | B cells                                 | Death            |
| Lueangarun et al.   | 1        | 28         | M      | Large B cells                           | Cure             |
| Jaremko et al.      | 1        | –          | –      | –                                       | –                |
| Dang et al.         | 1        | –          | –      | –                                       | –                |
| Rispensela et al.   | 1        | 14         | M      | Lymphoplasmocytic and Burkitt           | –                |
| Cajaiba et al.      | 1        | 6          | F      | Lymphoblastic T-cells                   | –                |
| Dohi et al.         | 1        | 50         | F      | Large B cells                           | –                |
| Matsuzaki et al.    | 1        | 59         | M      | B cells                                 | Death            |
| Wertelecki et al.   | 1        | 16         | M      | Undifferentiated                        | Death            |
| Berman et al.       | 1        | 20         | F      | Burkitt                                 | Cure             |
| Zein et al.         | 1        | 47         | M      | Large B cells                           | –                |
| Kim et al.          | 1        | 77         | F      | Large B cells                           | Cure             |
| Herbert et al.      | 1        | –          | –      | Cutaneous T cells                       | –                |
| Braam et al.        | 1        | –          | –      | Cutaneous T cells                       | –                |
| Itoh et al.         | 1        | 65         | M      | T cells                                 | Death            |
| Uyttebroeck et al.  | 1        | 4          | F      | B cells                                 | Cure             |
| Stiller et al.      | 5        | 7/4/1/13/7 | M/1 F  | 3 T cells/centroblastic/B cells         | 3 deaths and 2 cures |
| Shearer et al.      | 1        | 17         | M      | Immunoblastic                           | –                |
| Agaimy et al.       | 1        | 51         | F      | Anaplastic large cells                  | Death            |
| Tsvetkova et al.    | 1        | –          | –      | HL                                      | –                |
| Schiff et al.       | 1        | 21         | F      | Burkitt                                 | Cure             |
| Barbaric et al.     | 5        | 2/10/15/7/14 | 5 M | 2 T cells/B cells/lymphoblastic/ large cells | 1 death and 4 cures |
| Trattner et al.     | 1        | 9          | F      | T cells                                 | Cure             |
| Kremen et al.       | 1        | –          | –      | Lymphocytic                             | –                |
| Kaplan et al.       | 2        | 1/2        | 2 F    | 2 lymphoblastic                         | 2 deaths         |
| Astigarraga Aguirre et al. | 1 | – | F | NHL | – |

–, absent data, not specified or not accessible; PEL, primary effusion lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.